HC Wainwright Reiterates Buy Rating for Trevi Therapeutics (NASDAQ:TRVI)

Trevi Therapeutics (NASDAQ:TRVI)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a research note issued on Wednesday,Benzinga reports.

A number of other brokerages also recently issued reports on TRVI. B. Riley reaffirmed a “buy” rating and set a $6.00 price target on shares of Trevi Therapeutics in a report on Monday, October 7th. Leerink Partners initiated coverage on shares of Trevi Therapeutics in a report on Monday, September 9th. They set an “outperform” rating and a $7.00 price target on the stock. Raymond James began coverage on shares of Trevi Therapeutics in a research note on Friday, August 30th. They issued an “outperform” rating and a $9.00 price target for the company. D. Boral Capital restated a “buy” rating and set a $21.00 price objective on shares of Trevi Therapeutics in a research report on Wednesday. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $8.00 target price on shares of Trevi Therapeutics in a research report on Wednesday. Eight analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, Trevi Therapeutics currently has an average rating of “Buy” and an average target price of $9.13.

Trevi Therapeutics Stock Performance

Shares of Trevi Therapeutics stock opened at $2.60 on Wednesday. The company has a 50-day simple moving average of $3.00 and a two-hundred day simple moving average of $2.91. The stock has a market capitalization of $199.85 million, a PE ratio of -5.91 and a beta of 0.96. Trevi Therapeutics has a 52-week low of $1.03 and a 52-week high of $4.00.

Trevi Therapeutics (NASDAQ:TRVI) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.01). During the same quarter in the prior year, the company earned ($0.08) EPS. As a group, equities research analysts forecast that Trevi Therapeutics will post -0.49 EPS for the current fiscal year.

Hedge Funds Weigh In On Trevi Therapeutics

A number of institutional investors have recently bought and sold shares of TRVI. Barclays PLC raised its position in shares of Trevi Therapeutics by 180.8% during the 3rd quarter. Barclays PLC now owns 95,232 shares of the company’s stock valued at $319,000 after purchasing an additional 61,317 shares during the period. Geode Capital Management LLC increased its stake in Trevi Therapeutics by 10.2% in the 3rd quarter. Geode Capital Management LLC now owns 1,264,166 shares of the company’s stock worth $4,223,000 after buying an additional 117,418 shares in the last quarter. State Street Corp raised its holdings in Trevi Therapeutics by 5.9% during the third quarter. State Street Corp now owns 952,912 shares of the company’s stock valued at $3,183,000 after acquiring an additional 53,051 shares during the period. Fred Alger Management LLC purchased a new position in shares of Trevi Therapeutics in the third quarter valued at about $256,000. Finally, Acuta Capital Partners LLC boosted its stake in shares of Trevi Therapeutics by 11.7% in the third quarter. Acuta Capital Partners LLC now owns 290,500 shares of the company’s stock worth $970,000 after acquiring an additional 30,500 shares during the period. 95.76% of the stock is owned by institutional investors.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.